Boehringer Ingelheim, a Germany-based drugs company, is preparing to start an early-stage corporate venturing fund. At the NCET2 Global 1000 conference last month, Martin Heidecker (pictured), director of the Boehringer Ingelheim Venture Fund, said he was in mid-October relocating from Germany to Boston, US, to help “access early-stage deals from universities” as part of a separate…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
